Genetic Technologies benefits from Healthy China Policy
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Genetic Technologies (ASX:GTG), a provider of world-leading genetic risk assessment test products, has announced the establishment of its Asian operations within the Hainan Resort Software Community (HRSC) Free Trade Zone.
The company’s move into Asia includes the formation of Genetic Technologies HK Limited (the Hong Kong holding company investment vehicle) and Hainan Aocheng Genetic Technologies Co. Ltd (HAGTCL).
Genetic Technologies has had significant success as an early-stage biotech with its proprietary BREVAGenplus clinically validated assessment test for non-hereditary breast cancer being a first to market product.
The company has had four patents granted in the US, with six pending that relate to breast cancer risk assessment, including markers for breast cancer and methods for genetic and genomic analysis.
With regard to the HAGTCL investment vehicle, it will operate from within the Medical Pilot Zone established in what is known as “the Hainan Smart City”, a precinct that already includes many world renowned technology companies.
Participants in the Hainan Medical Pilot Zone gain access to the Chinese healthcare market valued in excess of US$800 billion.
Companies approved to operate in China as part of the Hainan Free Trade Zone initiative can take advantage of significant tax benefits, subsidies and facilitated investment.
The underlying government policy supporting this initiative is important for a company such as Genetic Technologies, as its ‘Healthy China 2030 Policy’ demonstrates a commitment to investing in research that aims to achieve ‘prevention is better than the cure’ style of health outcomes.
Support from government and regulatory bodies
The Hainan Provincial Government has established a world-class technology zone in Hainan and Genetic Technologies is delighted to be one of only a few medical technology invitees to date.
In addition, the HRSC will also support the company’s Chinese market entry through the provision of a range of services.
These include office space in the Free Trade Zone precinct and complementary accommodation for company staff.
As well as receiving Chinese corporate registry support, Genetic Technologies would also be entitled to marketing assistance, providing a link with government sectors, hospitals and other Chinese based health enterprises.
Support in gaining FDA approval
Importantly, assistance would also be provided in obtaining China FDA approval for the group’s new and growing portfolio of genetic risk assessment tests, substantially fast tracking the pathway to sales process.
Genetic Technologies’ researchers would also benefit from access to test samples from the Chinese ethnic population, facilitating new product development.
The establishment of operations follows on from the formal invitation to Genetic Technologies from the Hainan Provincial Government received in August 2018.
At this stage, it was envisaged that a joint venture with Zishan would form part of its China initiative, however the joint venture approach will not be progressing at this time.
Instead, Genetic Technologies, through its wholly-owned subsidiary HAGTCL, will work to introduce its world-class genetic risk assessment tests to the Chinese market.
Facilitation of collaborative opportunities
Commenting on the benefits of the joint venture agreement, Paul Kasian, Genetic Technologies’ chairman and chief executive said, “This initiative is likely to include partnering with Chinese health and medical distribution companies and CFDA accredited genetic testing laboratory operations.
“The Hainan Provincial Government team will help us find appropriate collaboration partners in mainland China.
“The establishment of operations in Hainan China is a significant step to advance the adoption of genetic risk assessment tests in China and in due course other parts of Asia.
“We are grateful for the support we have received from HRSC to date and acknowledge their commitment to continue to work with GTG to provide a meaningful contribution to the Healthy China 2030 Policy.”
Genetic Technologies will be paying its part in growing the suite of world-leading genetic risk assessment test products that will become central to China’s future preventative medicine activities.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.